Literature DB >> 22118926

Incidence of maxillary sinusitis and oro-antral fistulae in bisphosphonate-related osteonecrosis of the jaw.

Gerson Mast1, Sven Otto, Thomas Mücke, Christian Schreyer, Oliver Bissinger, Andreas Kolk, Klaus Dietrich Wolff, Michael Ehrenfeld, Stephen R Stürzenbaum, Christoph Pautke.   

Abstract

OBJECTIVE: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a serious side-effect of bisphosphonate therapy. In the majority of cases BRONJ occurs in the mandible. As a consequence a detailed investigation of BRONJ of the maxilla and in particular of involvement of the maxillary sinus has largely so far been neglected. The aim of this study was to analyse the frequency of maxillary sinusitis and oro-antral fistulae in BRONJ of the maxilla. SUBJECTS AND METHODS: A retrospective multicentre analysis was carried out in three Departments of Oral and Maxillofacial Surgery focussing on patients suffering from BRONJ in the maxilla. The role of involvement of the maxillary sinus, in particular sinusitis and oro-antral fistula, was analysed.
RESULTS: Out of a total of 170 patients suffering from BRONJ 53 cases (31.2%) with involvement of the maxilla were identified. At least one sign of maxillary sinusitis was present in 43.6% (23/53) and an oro-antral fistula in the course of the disease was detected in 35.8% (19/53) of those patients. The mean length of time of bisphosphonate intake was 36.16±16.32 months. Zoledronate was most frequently associated (60.4%) with symptoms, followed by the combination of Zoledronate/Ibandronate (13.2%), and Zoledronate/Pamidronate or Pamidronate alone (both 7.5%).
CONCLUSION: Maxillary sinusitis and oro-antral fistulae are associated with a BRONJ manifestation in the upper jaw in approximately 44%. The involvement of the maxillary sinus should be given special attention and three-dimensional imaging modalities might be necessary, not only to evaluate the extent of necrosis, but also to exclude involvement of the maxillary sinus.
Copyright © 2011 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22118926     DOI: 10.1016/j.jcms.2011.10.012

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  9 in total

1.  Treatment of stage II medication-related osteonecrosis of the jaw with necrosectomy and autologous bone marrow mesenchymal stem cells.

Authors:  Pit Jacob Voss; Akihiko Matsumoto; Esteban Alvarado; Rainer Schmelzeisen; Fabian Duttenhöfer; Philipp Poxleitner
Journal:  Odontology       Date:  2017-02-20       Impact factor: 2.634

2.  Surgical treatment of 61 consecutive patients with maxillary stage 3 medication-related osteonecrosis of the jaws using a pedicled buccal fat pad.

Authors:  Sanne Werner Moeller Andersen; Ditte Gertz Mogensen; Morten Schioedt; Thomas Kofod
Journal:  Oral Maxillofac Surg       Date:  2022-04-01

3.  Retrospective Analysis of Treatment Outcomes of Maxillary Sinusitis Associated with Medication-Related Osteonecrosis of the Jaw.

Authors:  Mitsunobu Otsuru; Saki Hayashida; Kota Morishita; Maho Murata; Sakiko Soutome; Miho Sasaki; Yukinori Takagi; Misa Sumi; Masahiro Umeda
Journal:  Int J Environ Res Public Health       Date:  2022-06-17       Impact factor: 4.614

4.  Management of Large Oroantral Fistulas Caused by Medication-Related Osteonecrosis with the Combined Sequestrectomy, Buccal Fat Pad Flap and Platelet-Rich Fibrin.

Authors:  Alparslan Esen; Sebnem Akkulah
Journal:  J Maxillofac Oral Surg       Date:  2019-08-30

5.  Treatment of bisphosphonate-related osteonecrosis of the jaws - a report of seven cases.

Authors:  Joanna Jakiel; Mansur Rahnama; Joanna Szczerba-Gwóźdź
Journal:  Contemp Oncol (Pozn)       Date:  2017-01-12

Review 6.  Medication-related osteonecrosis of the jaw: Prosthodontic considerations.

Authors:  Islam E Ali; Yuka Sumita
Journal:  Jpn Dent Sci Rev       Date:  2021-12-18

Review 7.  Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ).

Authors:  Sven Otto; Suad Aljohani; Riham Fliefel; Sara Ecke; Oliver Ristow; Egon Burian; Matthias Troeltzsch; Christoph Pautke; Michael Ehrenfeld
Journal:  Medicina (Kaunas)       Date:  2021-05-09       Impact factor: 2.430

8.  Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature.

Authors:  F Longo; A Guida; C Aversa; E Pavone; G Di Costanzo; L Ramaglia; F Ionna
Journal:  Int J Dent       Date:  2014-06-10

9.  Sinusitis and oroantral fistula in patients with bisphosphonate-associated necrosis of the maxilla.

Authors:  Pit Jacob Voss; Gustavo Vargas Soto; Rainer Schmelzeisen; Kiwako Izumi; Andres Stricker; Gido Bittermann; Philipp Poxleitner
Journal:  Head Face Med       Date:  2016-01-06       Impact factor: 2.151

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.